Among patients with gastrointestinal (GI) disease, treating iron deficiency anemia (IDA) with intravenous (IV) iron correlates with fewer hospital admissions vs oral iron.
Why this matters
- IDA commonly accompanies GI disease.
- IV iron replacement bypasses GI malabsorption.
- 1491 first encounters (24%) involved IV and 4803 (76%) involved oral iron treatment.
- Among first encounters in which oral iron was used, 3683 (77%) were followed by another encounter within 30 days, vs 504 (34%) of those that used IV iron (aOR, 0.52; 95% CI, 0.44-0.61).
- Among 1464 first and second encounters for which visit types were available:
- Those initially treated with IV iron (n=176) had 70% elective and 30% emergency second encounters;
- Those initially treated with oral iron (n=533) had 83% emergency and 17% elective second encounters.
- Retrospective population-based cohort study of 2 British databases.
- Researchers captured ~3 years of healthcare encounters of patients with GI disease and IDA (2844 patients; 6294 encounters).
- Patients were treated with oral or IV iron at initial encounters.
- Outcome: elective and emergency reencounters within 30 days of initial encounter.
- Funding: Vifor Pharma UK Ltd., which makes IV iron.
- Retrospective study; few patients treated by IV iron.
- P-values not reported.